Also known as: cannabis for lumbar pain · THC and lower back pain · marijuana for sciatica

Cannabis and Lower Back Pain

Evidence review of cannabinoids for chronic low back pain and related conditions.

Automated fact-check pass
17 cited sources
Published
Last reviewed
How this page was made

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

↯ The honest take

Cannabis appears to help some people sleep through back pain and may reduce opioid use. The clearest trial evidence is for neuropathic pain (sciatica-type symptoms) and sleep disruption, not garden-variety mechanical low back strain. Most controlled studies focus on other chronic pain types, not low back pain specifically. Real-world users report benefit, but that's weaker evidence than controlled trials. It's not a replacement for exercise, physical therapy, or proper diagnosis.

Not medical advice

This article is educational, not medical advice. Lower back pain has many causes — some benign, some serious (cauda equina syndrome, fracture, infection, malignancy). Red-flag symptoms like saddle anesthesia, bladder or bowel changes, progressive weakness, fever, or unexplained weight loss require urgent medical evaluation, not cannabis. Talk to a clinician familiar with your history before using cannabis for pain, especially if you take other medications, are pregnant, have a psychiatric history, have cardiovascular disease, or use opioids or other CNS depressants.

Plain-language summary

Most adults will have low back pain at some point. About 20% develop chronic symptoms lasting beyond three months Strong evidence[1]. People reach for cannabis for two reasons: pain itself, and the sleep, anxiety, and muscle tension that come with it.

The overall picture from controlled trials: cannabinoids produce a small-to-moderate reduction in chronic pain scores compared to placebo, with effect sizes similar to other adjunctive pain medications Strong evidence[2]. Most of that trial evidence is for neuropathic pain and cancer pain — not specifically low back pain. Trials specific to low back pain are few and small Weak / limited. Real-world surveys and observational studies show users report benefit and reduced use of other analgesics, but observational data is not a controlled trial Weak / limited[4].

What probably works

Chronic pain with a neuropathic component. When low back pain includes radiculopathy (sciatica), burning, or shooting pain from nerve root irritation, oral or oromucosal THC:CBD products show modest benefit in meta-analyses of chronic neuropathic pain Strong evidence[5]. Nabiximols (Sativex, a 1:1 THC:CBD spray) has mixed chronic pain data; its trials are not specific to low back pain but include neuropathic and musculoskeletal chronic pain populations Weak / limited[6].

Pain-related sleep disruption. THC at low-to-moderate doses reduces sleep latency and nighttime awakenings in chronic pain patients Strong evidence[3]. For people whose back pain wrecks their sleep, this is often the most reliable benefit they notice.

Reducing opioid dose. Observational and some prospective data suggest people using cannabis for chronic pain often reduce opioid use Weak / limited[4][7]. This is not the same as proving cannabis treats the pain better — it may be substitution — but for harm reduction it matters if total opioid exposure declines.

What might work

Muscle spasm. THC has documented antispasticity effects in multiple sclerosis Strong evidence[6], but extrapolating to ordinary paraspinal muscle spasm in low back pain is not supported by controlled trials. Patients report relief; controlled data for low back muscle spasm specifically is absent Anecdote.

CBD alone. CBD is the most heavily marketed product for back pain. Trial evidence for oral CBD in chronic non-cancer pain is mixed and mostly negative or null at the doses people actually take (typically 10–50 mg/day, versus 200–800 mg/day in trials) Weak / limited[8]. Topical CBD has some signal in peripheral neuropathy Weak / limited[9] but low back pain is mostly deep tissue — topical absorption to the spine is unlikely.

Inflammation in degenerative disc disease. Cannabinoids reduce inflammatory markers in animal models of disc degeneration Weak / limited[10]. No human disc disease trials exist.

What doesn't work or has weak evidence

Acute low back pain (the first few weeks). No controlled evidence supports cannabis for acute lumbar strain. Standard guidance — stay active, NSAIDs if appropriate, avoid prolonged bed rest — has far better evidence Strong evidence[1].

"Indica for pain, sativa for energy." This is dispensary folklore, not pharmacology. The cannabinoid and terpene profile (chemovar) varies enormously within both labels, and the indica/sativa classification does not predict effects in any controlled study Disputed[11].

Terpene-specific claims. The often-repeated "myrcene 0.5% threshold" for sedation has no clinical evidence behind it. Terpenes may contribute to overall effects (the "entourage effect"), but human evidence is limited and specific marketing claims lack verification Disputed[12].

Curing disc herniation or structural pathology. No evidence. Cannabis modulates pain perception; it does not repair tissue.

What we don't know

These are genuine gaps, not rhetorical hedging. The controlled trials needed to answer them have not been conducted.

Comparison with standard treatments

Current guidelines for chronic low back pain (American College of Physicians, NICE) prioritize exercise, physical therapy, and cognitive-behavioral therapy as first-line, with NSAIDs, duloxetine, and limited opioids as pharmacological options Strong evidence[1][14]. None of these are dramatically effective — chronic low back pain is hard to treat across the board.

Rough comparison of effect sizes from meta-analyses of chronic pain:

Cannabis is plausibly in the same ballpark as duloxetine or NSAIDs, with a different side-effect and withdrawal profile. It is not a substitute for exercise and rehabilitation.

Risks and side effects

A reasonable approach if you and your clinician decide to try cannabis: start low (e.g., 2.5 mg THC oral, or balanced THC:CBD), go slow, track whether function — not just pain score — actually improves over 4–6 weeks, and stop if it doesn't. Monitor for dose escalation.

Sources

  1. Peer-reviewed Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. 2017;166(7):514-530.
  2. Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473.
  3. Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. 2017.
  4. Peer-reviewed Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. Journal of Pain. 2016;17(6):739-744.
  5. Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;(3):CD012182.
  6. Peer-reviewed Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chemistry & Biodiversity. 2007;4(8):1729-1743.
  7. Peer-reviewed Vigil JM, Stith SS, Adams IM, Reeve AP. Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLoS ONE. 2017;12(11):e0187795.
  8. Peer-reviewed Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain. Journal of Cannabis Research. 2021;3(1):22.
  9. Peer-reviewed Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Current Pharmaceutical Biotechnology. 2020;21(5):390-402.
  10. Peer-reviewed Silveira JW, Issy AC, Castania VA, et al. Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration. PLoS ONE. 2014;9(12):e113161.
  11. Peer-reviewed Piomelli D, Russo EB. The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. 2016;1(1):44-46.
  12. Peer-reviewed Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-1364.
  13. Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
  14. Peer-reviewed Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-2809.
  15. Peer-reviewed Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986.
  16. Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
  17. Government National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE guideline NG59. 2016 (updated).

How this page was made

Generation history

Oct 30, 2026
Revision
Oct 29, 2026
Fact-check pass — raised 7 flags
May 31, 2026
Self-review — raised 2 flags
May 11, 2026
Fact-check pass — raised 3 flags
May 11, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.